Jean-Paul Kress
Präsident bei Syntimmune, Inc.
Vermögen: - $ am 31.05.2024
Profil
Dr. Jean-Paul Kress, MD, is a President & Director at Syntimmune, Inc. He is on the Board of Directors at Syntimmune, Inc. Dr. Kress was previously employed as a CEO & Chairman-Management Board by MorphoSys AG, a Chairman by ERYTech Pharma SA, a Member-Supervisory Board by Quantum Genomics SA, a President-International & Executive Vice President by Biogen, Inc., an Independent Director by Sarepta Therapeutics, Inc., a Senior Vice President & Head-North America by Genzyme Corp., and a President & Chief Executive Officer by Sanofi Pasteur MSD SNC.
He received his undergraduate degree from École Normale Supérieure, a graduate degree from École Normale Supérieure and a doctorate degree from Faculté De Médecine Necker Enfants Malades Université.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.12.2022 | 0 ( -.--% ) | - $ | 31.05.2024 |
Aktive Positionen von Jean-Paul Kress
| Unternehmen | Position | Beginn |
|---|---|---|
Syntimmune, Inc.
 Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Präsident | 03.01.2018 |
Ehemalige bekannte Positionen von Jean-Paul Kress
| Unternehmen | Position | Ende |
|---|---|---|
| MORPHOSYS AG | Vorstandsvorsitzender | 06.06.2024 |
ERYTech Pharma SA
 ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | Vorsitzender | 23.06.2023 |
| QUANTUM GENOMICS | Direktor/Vorstandsmitglied | 24.06.2019 |
| BIOGEN INC. | Corporate Officer/Principal | 01.01.2018 |
| SAREPTA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 06.06.2017 |
Ausbildung von Jean-Paul Kress
| École Normale Supérieure | Graduate Degree |
| Faculté De Médecine Necker Enfants Malades Université | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| BIOGEN INC. | Health Technology |
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| MORPHOSYS AG | Health Technology |
| QUANTUM GENOMICS | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Health Technology |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | Health Technology |
Sanofi Pasteur MSD SNC
 Sanofi Pasteur MSD SNC Pharmaceuticals: MajorHealth Technology Sanofi Pasteur MSD SNC is engaged in the wholesale of pharmaceutical products. The company was founded on August 16, 1993 and is headquartered in Lyon, France. | Health Technology |